Sun Pharma Advanced Research Company Ltd announced an investor presentation on December 19, 2024, detailing updates on clinical programs and their R&D pipeline. The presentation includes data from the PROSEEK Phase 2 study in Parkinson's disease, which ultimately did not meet its primary endpoint, showing mixed results from the treatment evaluated.